Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer.
10.1016/j.apsb.2023.05.005
- Author:
Yubo WANG
1
;
Jian MIN
2
;
Xiangping DENG
1
;
Tian FENG
1
;
Hebing HU
2
;
Xinyi GUO
1
;
Yan CHENG
1
;
Baohua XIE
1
;
Yu YANG
2
;
Chun-Chi CHEN
2
;
Rey-Ting GUO
2
;
Chune DONG
1
;
Hai-Bing ZHOU
1
Author Information
1. Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China.
2. State Key Laboratory of Biocatalysis and Enzyme Engineering, National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, Hubei Key Laboratory of Industrial Biotechnology, School of Life Sciences, Hubei University, Wuhan 430062, China.
- Publication Type:Journal Article
- Keywords:
Covalent strategy;
Endocrine-resistant breast cancer;
Estrogen receptor degraders;
X-ray crystallography
- From:
Acta Pharmaceutica Sinica B
2023;13(12):4963-4982
- CountryChina
- Language:English
-
Abstract:
Endocrine-resistance remains a major challenge in estrogen receptor α positive (ERα+) breast cancer (BC) treatment and constitutively active somatic mutations in ERα are a common mechanism. There is an urgent need to develop novel drugs with new mode of mechanism to fight endocrine-resistance. Given aberrant ERα activity, we herein report the identification of novel covalent selective estrogen receptor degraders (cSERDs) possessing the advantages of both covalent and degradation strategies. A highly potent cSERD 29c was identified with superior anti-proliferative activity than fulvestrant against a panel of ERα+ breast cancer cell lines including mutant ERα. Crystal structure of ERα‒ 29c complex alongside intact mass spectrometry revealed that 29c disrupted ERα protein homeostasis through covalent targeting C530 and strong hydrophobic interaction collied on H11, thus enforcing a unique antagonist conformation and driving the ERα degradation. These significant effects of the cSERD on ERα homeostasis, unlike typical ERα degraders that occur directly via long side chains perturbing the morphology of H12, demonstrating a distinct mechanism of action (MoA). In vivo, 29c showed potent antitumor activity in MCF-7 tumor xenograft models and low toxicity. This proof-of-principle study verifies that novel cSERDs offering new opportunities for the development of innovative therapies for endocrine-resistant BC.
